# The VO2 Increase With Testosterone Addition - Heart Failure (VITA-HF) Trial

Study · id `cardio:ct-nct01469988` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01469988](<https://clinicaltrials.gov/study/NCT01469988>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01469988

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It plans to enroll 318 participants.

## Technical summary

Registry record NCT01469988. Randomized; double masking; primary purpose treatment. Start 2012-11 (registry gives no type); primary completion 2014-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 318 participants (planned count; ClinicalTrials.gov record NCT01469988, source copy `cardio:ctgov-nct01469988-2018-01-23`, retrieved 2026-10-26)
- Start date: 2012-11 (registry gives no type) (ClinicalTrials.gov record NCT01469988, source copy `cardio:ctgov-nct01469988-2018-01-23`, retrieved 2026-10-26)
- Primary completion: 2014-04 (actual) (ClinicalTrials.gov record NCT01469988, source copy `cardio:ctgov-nct01469988-2018-01-23`, retrieved 2026-10-26)
- Completion: 2014-04 (actual) (ClinicalTrials.gov record NCT01469988, source copy `cardio:ctgov-nct01469988-2018-01-23`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT01469988, source copy `cardio:ctgov-nct01469988-2018-01-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01469988-2018-01-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: The VO2 Increase With Testosterone Addition - Heart Failure (VITA-HF) Trial
- Acronym: VITA-HF
- Condition: Heart Failure
- Intervention (Drug): Testosterone
- Lead sponsor: University of Alberta
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: University of Alberta (`cardio:org-university-of-alberta`)

## Provenance

Content hash: d2f9db37db907be94e02bc5b1c6c79c155b4d4c5ad9cea5173da951cb9e836c1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
